bluuebunny/crossref_metadata_2025_split huggingface dataset:
P01-29 - Depression in Parkinson's Disease- Searching for the most Potent Antidepressant
Authors: Djokic G. , Zivkovic N. , Pavicevic D. , Lazic D. 
Published: June 2010

Depression occures in 28- 60% of patients with PD. There is little evidence of the efficacy and safety of antidepressant therapies in Parkinson's disease. This interventive, paralel, RTC, safety/efficiency study included 339 patients aged 36-90, with ICD10/DSMIV criteria for PD and depression. Purpose of the study was to estimate depression, quality of life, and severity od PD symtoms after 3 months of antidepressant therapy.MethodsWe have randomly divide patients into control group(N=45) without antidepressants, and experimental groups in accordance with applied antidepressants: clomipramine(N=48), fluoxetine (N=49), sertraline (N=51), escitalopram (N=49), mirtazepine (N=45), and tianeptine (N=52). We have used HAMD for estimation of depression, QOL scale for quality of life, and UPDRS subscales I(behaviour and mood) and II(daily activities) for PD symptoms at pretrial, and after 3 months scores in all groups. Data were processed with SPSS for Windows.ResultsThere is no statistical significance in pretrial scores between groups. After 3 months there is: significant increase in control and significant discrease(p=0.000) of HAMD scores in all experimental groups, in favour of antidepressant with higher mediana(escitalopram 9; sertralin 8; tianeptin 6;clompramin 3; mirtazapin 3;fluoxetine 1; control -2); significant increase of QOL scores in favour of antidepressant with higher mediana(escitalopram 1.24; sertraline 1.12; tianeptine 0.65; clomipramine 0.40; mirtazapine 0.27; fluoxetine 0.27), and significant difference in UPDRS II pretrial and after 3 months subscores(p=0.016), in favour of escitalopram.ConclusionAll tested antidepressant are efficient in reducing HAMD score, but only escitalopram,sertraline,and tianeptine improved HAMD, QOL, UPDRS I, and II scores without side effects.
P01-35 - Fatigue in Female Patients with Major Depression: the Effect of age at Onset
Authors: Ferentinos P. , Kontaxakis V. , Havaki-Kontaxaki B. , Papadimitriou G. , Lykouras L. 
Published: June 2010

ObjectivesThis study aimed to investigate the independent correlation of the severity of fatigue in female patients with Major Depressive Disorder (MDD) with age at illness onset.MethodsWe studied 70 female patients (34 inpatients), aged 23-65 years (mean 48.2±10.6 years), with MDD as assessed with the M.I.N.I. version 5.0.0. All patients were currently in a Major Depressive Episode, with a 17-item Hamilton Depression Rating Scale (HDRS) score ≥17, and free of major fatigue-associated conditions. Reported fatigue was assessed with the 14-item Fatigue Questionnaire (FQ). Pearson's (r) or Spearman's (rho) correlations between FQ, age, inpatient status, HDRS and age at onset were calculated. A multiple regression analysis was then performed, with FQ as the dependent variable.ResultsThe FQ score was significantly correlated with HDRS (r=0.406, p< 0.001) and age at onset (r=-0.281, p=0.02). In the multiple regression model, HDRS and age at onset turned out as significant independent predictors of the FQ score, with standardised beta coefficients of 0.419 (p< 0.001) and -0.3 (p=0.006), respectively (R2=0.255).ConclusionsThe severity of fatigue in female patients with major depression is independently correlated with earlier age at illness onset.
P01-37 - Effects of Testosterone Supplementation on Depressive Symptoms in Hypogonadal men with the Metabolic Syndrome: The Moscow Study
Authors: Giltay E.J. , Tishova Y.A. , Mskhalaya G.J. , Gooren L.J.G. , Saad F. , Kalinchenko S.Y. 
Published: June 2010

IntroductionLow testosterone levels in men are associated with the metabolic syndrome (MetS) as well as with depressive symptoms, low vitality and sexual dysfunction.ObjectivesTo assess the effects of testosterone administration on these subjective symptoms, which have not extensively been studied in hypogonadal men with the MetS.MethodIn a randomized, placebo-controlled, double-blind, phase III trial, 184 men suffering from both the MetS and hypogonadism were included. They were treated for 30 weeks with either parenteral testosterone undecanoate (TU; 1000 mg IM testosterone undecanoate, at baseline, and after 6 and 18 weeks; Nebido®) or placebo injections. 105 (92.9%) men receiving TU and 65 (91.5%) receiving placebo completed the 30 week trial. The Beck Depression Inventory (BDI), Aging Males’ Symptoms (AMS) scale, and International Index of Erectile Function 5-item (IIEF-5) scale at baseline, 18 and 30 weeks were analysed using multilevel analysis.ResultsThe mean age was 52.1 years (range: 35-69), with a mean body mass index of 35.5 kg/m2 (SD 6.7), and a mean total testosterone level of 8.0 nmol/L (SD 4.0). There were significant improvements in BDI (mean difference vs. placebo after 30 weeks: -2.5 points; 95% confidence interval [CI]: -0.9;-4.1; P=0.003), AMS (-7.4 points; 95% CI: -4.3;-10.5; P< 0.001), and IIEF-5 (+3.1 points; 95% CI: +1.8;+4.4; P< 0.001). The effects were strongest in men with baseline total testosterone levels < 7.7 mmol/L.ConclusionsTU administration may improve depressive symptoms, aging male symptoms and sexual dysfunction in hypogonadal men with the MetS.
P01-41 - Age of Onset in Psychotic Unipolar Depression: a Comparative Clinical Study
Authors: Gournellis R. , Oulis P. , Rizos E. , Tournikioti K. , Michopoulos I. , Lykouras L. 
Published: June 2010

ObjectiveThe issue whether the clinical characteristics of unipolar psychotic major depression (PMD) vary according to the age of onset remains still unclear. In this study we assess comparatively the clinical characteristics of young early-onset (n=30), elderly early-onset (n=34) and elderly late-onset (n=35) psychotic depressives.MethodsNinety-nine inpatients suffering from DSM IV unipolar PMD were assessed on the basis of SCID IV, HRSD and a physical impairment rating scale.ResultsThe elderly late-onset patients suffered from overall more severe depression compared to both categories of early-onset ones, more gastrointestinal symptoms compared to young early-onset patients and more psychic anxiety compared to elderly early-onset patients. Moreover, they expressed significantly more frequently delusions of somatic content and had higher scores on the HRSD item of hypochondriasis than their young early-onset counterparts. The group of elderly early-onset PMD patients was found to hold an intermediate position between the young early-onset and elderly late-onset PMD patients with regard to hypochondriacal ideation, gastrointestinal symptoms and delusions of somatic, guilt and paranoid content.ConclusionsThe findings of the present study suggest considerable differences between young, elderly early-onset and elderly late-onset PMD patients with respect to their clinical features.
P01-43 - Management of Comorbid Addictive Disorders in Bipolar Disorder Recommendation Formalized of French Expert in Bipolar
Authors: Guillaume S. , Samalin L. , Abbar M. , Meynard J.A. , Gay C. , Martin P. , Llorca P.M. , Courtet P. ,   l’ Association Francaise de Psychiatrie Biologique (AFPB)
Published: June 2010

ObjectiveAs part of a process to improve bipolar disorders (BPD) treatment and outcome in France, AFBP developed recommendations in the management of patients with bipolar disorders for French practitioners. The recommendations aim to reflect both evidence-based practice and real-world experience. Here, we will focus on the management of BPD with comorbid addictive disorders.MethodA formalized method by expert consensus panel was used. 239 questions were developed and sent to a panel of 40 French experts in order to assess six domains:1)screening and diagnosis,2)acute phase treatment,3)maintenance and non pharmacological treatment,4)somatic comorbidities,5)psychiatric comorbidities and suicide risk management and6)special populations.Special attention was made to situations where evidence based treatment are lacking.ResultsThe treatment of BPD and comorbid addictive disorders should be concurrent. The only exception is during an alcohol withdrawal where mood state may be reassessed for a second time. Experts recommend the use of atypical antipsychotics or anticonvulsants during a manic, mixed or depressive episode as well as in prophylaxia. During a depressive episode, the adjunction of an antidepressant may be considered. If adjunctive sedative treatment is necessary, a sedative classical antipsychotic seems to be a better choice that benzodiazepine. Substitution treatment for opioid must not be stopped. A psychotherapy focused on the addiction should be systematic in susbtance dependence and proposed in substance abuse.ConclusionThe French expert panel recommends different therapeutic options for patients with dual diagnosis compared to usual BPD patients.
P01-47 - A Comparison of Life Events in Patients with adult-onset Unipolar Disorder, adult-onset Bipolar Disorder and Controls
Authors: Horesh-Reinmann N. 
Published: June 2010

ObjectiveThe present study aimed to explore the association between stressful life events (LE) and the development of affective psychopathology.MethodThirty patients with unipolar disorder and 30 patients with bipolar disorder were compared to 60 matched healthy controls as regards the rate of stressful LE. Measures included the Beck Depression Inventory, the Adult Life Events Checklist and the Childhood Life Events Questionnaire.ResultsThe entire sample had more LE in general, more negative and loss-related LE in the year preceding their first depressive episode as compared to normals. Subjects with unipolar disorder had more positive LE and more achievement LE, whereas subjects with bipolar disorder had more uncontrollable LE in the year preceding the first depressive episode. The relationship between LE and manic episodes was prominent in the year preceding the first manic episode, with bipolar subjects reporting more LE in general and more ambiguous events in that year. A significant relationship was found between childhood LE and the development of affective disorders in adulthood, with unipolars exhibiting less positive and achievement LE.ConclusionsThe major impact of LE on the onset of affective disorders was found in the year prior to the first depressive or manic episodes, in the unipolar and bipolar groups. This suggests that the accumulation of LE at this crucial period contributes to the precipitation of a pathological response mechanism. Once established, this mechanism would be reactivated in the future by even less numerous and less severe stressors, compatible with the kindling hypothesis.
P01-60 - Irrational Beliefs of Patients with Major Depressive Disorder
Authors: Mandic V. , Perunicic I. , Lukic B. , Rakovic I. , Marjanovic S. , Lecic Tosevski D. 
Published: June 2010

ObjectiveAccording to CBT theory, belief system has an important role in etiology of depression. Absolutistic, rigid and irrational beliefs might have influence on development and persistence of depressive psychopathology. The aim of our study was to examine characteristics of irrational beliefs in the cognitive scheme of patients with Major Depressive Disorder (MDD).MethodThe sample consisted of sixty inpatients diagnosed as MDD by using the ICD-X criteria. The assessment of irrational beliefs was carried out by Beck's Personality Belief Questionnaire (PBQ).ResultsOur findings have shown that irrational beliefs related to histrionic, schizoid and paranoid cognitive system were the most prevalent in patients with MDD. We also found significant and high correlation between opposite way of thinking - histrionic beliefs pattern correlated with avoidant and schizoid beliefs patterns. Also, dependent belief pattern was in a significant correlation with avoidant, schizoid and paranoid beliefs. In addition to rigidity, absolutistic and imperative cognitive schemes, we also found ambivalent cognitive tendencies. The existing ambivalence could be an important factor in the maintenance of depressive symptoms.ConclusionOur study has shown high prevalence of irrational beliefs in MDD patients. By recognizing the exact cognitive biases underlying depression, it might be possible to direct the therapeutic interventions more specifically and provide a highly personalized approach in the treatment of patients with MDD. We also believe that there is a need for a psychotherapeutic work on irrational beliefs during remission, which might prevent relapses.
P01-64 - Treatment of Depression in a British Community Mental Health Team; can Patients be Treated in Primary Care?
Authors: Butler S. , Agius M. , Zaman R. 
Published: June 2010

BackgroundPatients who can be treated in Primary care should receive their treatment in Primary Care.Aims/ObjectivesWe aim to identify depression treatments used by Bedford East Community Psychiatric Team (BECMHT) and hence identify those patients who could be appropriately managed in Primary care.MethodsWe identified 299 patients from the BECMHT database with depression (F32,F33, F41.2 and uncoded). Potential patient groups to discharge were identified by analysing these patients’ data; their medications were compared to NICE guidelines and other evidence-based-treatments.ResultsMany patients were on different combinations of medications but there were 153 (51.2%) on one antidepressant only. Half of the patients’ medication was in accordance with NICE guidelines (157/52.5%), 11 patients were on medication with a different evidence-base and 101 patients were on medication without either of these. However, 36.5% of patients had an inter-current psychiatric diagnosis.ConclusionsPrescribing patterns within BECMHT demonstrate groups of patients who are more likely to need Secondary care, including those with inter-current psychiatric diagnosis and patients on medications that are not backed by NICE or a known evidence-base. Provided adequate symptom control, the patients who could be discharged include those on one antidepressant and patients on medications in conformity with NICE guidelines who do not need monitoring in secondary care. The patient's notes should be reviewed before discharge to ensure adequate future treatment. There should be good communication with Primary care, with joint protocols and the possibility for patients to easily access services appropriate to their needs.
P01-69 - Long-term Asenapine Treatment for Bipolar Disorder: a Double-blind 40-week Extension Study
Authors: McIntyre R. , Cohen M. , Zhao J. , Alphs L. , Macek T. , Szegedi A. , Panagides J. 
Published: June 2010

ObjectivesAsenapine is indicated in adults for acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder with or without psychotic features. We report the safety, tolerability, and efficacy of asenapine in patients with bipolar I disorder completing up to 52 weeks of treatment.MethodsPatients completing either of two 3-week efficacy trials and a 9-week double-blind extension were eligible for this 40-week double-blind extension. Patients in the 3-week trials were randomized to flexible-dose asenapine (5 or 10 mg BID), placebo, or olanzapine (5-20 mg QD; included for assay sensitivity only). Patients entering the extension continued their preestablished treatment; those originally randomized to placebo received flexible-dose asenapine (placebo/asenapine, 5 or 10 mg BID). Safety and tolerability endpoints included adverse events (AEs), extrapyramidal symptoms, laboratory values, and anthropometric measures. Efficacy was measured as the change in Young Mania Rating Scale (YMRS) total score from 3-week trial baseline to week 52; the placebo/asenapine group was included in the safety analyses.ResultsIncidence of treatment-emergent AEs was 71.9%, 86.1%, and 79.4% with placebo/asenapine, asenapine, and olanzapine, respectively. The most frequent AEs included headache and somnolence (placebo/asenapine); insomnia, sedation, and depression (asenapine); and weight gain, somnolence, and sedation (olanzapine). Mean ± SD changes in YMRS score at week 52 among observed cases in the intent-to-treat population were -28.6±8.1 for asenapine and -28.2±6.8 for olanzapine.ConclusionsIn this 52-week study, asenapine was well tolerated and long-term maintenance of efficacy was supported in patients initially presenting with bipolar mania.
P01-70 - Complexity Analysis of Brain's Activity in Major Depression using Magnetoencephalography (MEG)
Authors: Méndez Hernández M.A. , Fernández Lucas A. , Hornero R. , Zuluaga P. , Rodriguez-Palancas A. , Ortiz T. 
Published: June 2010

IntroductionPrevious studies have suggested structural and physiological changes in Major Depressive Disorder (MDD). Unfortunately, there isn’t a consensus when defining the neuropathophysiology of depression. Hence, there isn’t a biological measure used in the clinical practice to define the differences between patients with depression and controls.ObjectiveTo test differences in Lempel-Ziv complexity (LZC) values between patients with major depression and controls.MethodsComparison of spontaneous oscillatory neuromagnetic activity using MEG between groups.Participants20 patients matching DSM IV-TR criteria for MDD, and 19 sex- and age-matched controls.ResultsWe found a significant positive correlation between age and LZC values within controls. This correlation was not found in MDD patients. Depressive subjects showed a tendency of higher LZC values when compared to controls. We found significant differences between groups in anterior and right regions. After six months of treatment with Mirtazapine (30 mg V.O. O.D.), we studied the Hamilton-17 rating scale values and found that this treatment was clinically effective in most patients. The main pharmacological treatment's effect was besides reducing the LZC values in patients, to recuperate the tendency observed in controls.ConclusionsWe could suggest that there is a relationship between a physiological metric and depression as well as symptom relief or remission after an effective treatment. According to our results we found physiological changes in the brain dynamic in depressive patients when compared to controls which means there are neurophysiological changes in depressive patients with time.
P01-74 - Beneficial Effects of Chronic Treatment with Agomelatine on the Anxiety-and Depression-like State Induced by Corticosterone in C57BL/6NTAC Mice
Authors: Rainer Q. , Gabriel C. , Mocaer E. , Xia L. , Hen R. , Enhamre E. , Guilloux J.P. , Gardier A.M. , David D.J. 
Published: June 2010

Recently, we have developed a novel paradigm appropriate and useful for screening early-stage and novel treatments for depression and anxiety based on the chronic delivery of corticosterone via the drinking water. Here, we investigated in mice the behavioral effects of agomelatine an antidepressant melatonergic (MT1/MT2) receptor agonist and 5-HT2C receptor antagonist on various paradigms predictive of antidepressant and anxiolytic activities such the Novelty Suppressed Feeding (NSF) test, the coat state, the splash test (grooming behavior), the Open Field paradigm (OF) and the home cage activity.Adult mice were treated for 8 weeks with vehicle or corticosterone (35 ug/ml/day) via the drinking water. During the final four weeks, animals were treated with either HEC1%, agomelatine (10 and 40 mg/kg, i.p) or fluoxetine (18 mg/kg, i.p.). Behavioral tests were performed during the last experimental week.Our results show that a chronic corticosterone treatment established a depressive/anxious-like phenotype in the NSF, OF and grooming behaviors. This state was reversed by a 4-week antidepressant treatment with agomelatine. Moreover, agomelatine blocked the impaired mice coat state induced by corticosterone. In agreement with its mechanism of action, agomelatine increased home cage activity (ratio dark phase/light phase) in both corticosterone and vehicle-treated mice suggesting an increase activity rhythms’ amplitude. Fluoxetine validated the behavioral models but without any effect on the synchronization of circadian rhythms. The present study suggests that agomelatine was able to reverse a depressive and anxious-like state in mice induced by elevation of glucocorticoid levels, results in line with the antidepressant/anxiolytic-like properties of the drug.
P01-76 - An Audit to Compare the Discharge Rates between Different Antidepressant Monotherapies Prescribed for Unipolar Depression
Authors: Agius M. , Gardner J. , Liu K. , Zaman R. 
Published: June 2010

BackgroundA recent metanalysis has demonstrated that there are differences in efficacy and acceptability of commonly prescribed anti-depressants (Cipriani et al. 2009). Escitalopram, sertraline, venlafaxine and mirtazapine were the most effective.ObjectiveWe wished to find out whether the data from our own practice corresponded with the data from the metanalysis.AimTo compare the efficacy of anti-depressant monotherapies in patients with unipolar depression at Bedford Hospital, using discharge rates as the outcome measure.MethodWe included all patients with unipolar depression on an antidepressant monotherapy in Bedford hospital in our analysis (145 in total). We examined the clinical notes for each patient to assess whether they had been discharged from the out-patient clinic after being prescribed the antidepressant. This allowed us to calculate discharge rates for each antidepressant monotherapy.ResultsA higher percentage of patients prescribed Escitalopram were discharged from clinic compared to theother anti-depressant monotherapies.DiscussionOur results support the findings of the meta-analysis. The discharge rates from Bedford hospital suggest that Escitalopram in particular is the most efficacious.ConclusionThis audit in a small group of patients suggests that Escitalopram leads to the highest discharge rate compared to the other monotherapies prescribed.
P01-77 - Working Memory Impairments in Patients with Major Depressive Disorder (M.D.D)
Authors: Nazarboland N. 
Published: June 2010

ObjectivesSince it has been shown that depressed individuals experience deficits in executive cognitive functions, current study investigates the impairments of working memory in patients suffering from major depressive disorder (M.D.D) in comparison with normal control group in terms of DSM-IV criteria.MethodThe two groups (25 patients and 25 normal) were matched via gender, age and education. All completed Beck Depression Inventory and participated in two working memory tasks: “Paced Auditory Serial Adding Test (PASAT)” and “Wechsler Digit Span Scale”.ResultsUsing T test for independent groups, the results indicated that the patient group were experiencing significant impairments in working memory in comparison with control group(p< 0.0001) and results of Regression Analysis showed that severity of depression has a significant effect on the amount of impairments that subjects had experienced in working memory.ConclusionDepression had impaired working memory performance in individuals and the amount of impairment will increase as the severity of depressive symptoms are increasing.